Disorders of phosphate homeostasis from CKD, vitamin D abnormalities, refeeding, or tumor lysis.
Also known as: hyperphosphatemia, hypophosphatemia, phosphate disorder, phosphorus disorder, refeeding syndrome
Overview
Hyperphosphatemia is serum phosphate >4.5 mg/dL in adults (>7 in young children). Hypophosphatemia is serum phosphate <2.5 mg/dL, with severe <1.0 mg/dL. Phosphate homeostasis is regulated by dietary intake, intestinal absorption (1,25-dihydroxyvitamin D dependent), renal excretion (PTH and FGF-23 dependent), and shifts between extracellular and intracellular compartments.
Epidemiology
Hyperphosphatemia is nearly universal in advanced CKD (eGFR <30) and end-stage renal disease. Hypophosphatemia occurs in ~5% of hospitalized patients and up to 30% of ICU patients, often from refeeding, sepsis, diabetic ketoacidosis recovery, or alcohol use disorder.
Try two board-style Hyperphosphatemia and Hypophosphatemia questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1RenalMedium
A 28-year-old woman with anorexia nervosa is admitted with a BMI of 13 kg/m². Enteral nutrition is started at full caloric goal on hospital day 1. Three days later she develops diffuse muscle weakness, paresthesias, and confusion, and she requires increasing respiratory support for shallow breathing. Laboratory studies show phosphate 0.8 mg/dL, potassium 2.9 mEq/L, and magnesium 1.2 mg/dL, with normal renal function. Which of the following is the most likely diagnosis?
AAcute refeeding syndrome
BTumor-induced osteomalacia
CX-linked hypophosphatemia
DAcute hungry bone syndrome
EAcquired Fanconi syndrome
Reveal answer & full explanation
Correct answer: A — Acute refeeding syndrome
AAcute refeeding syndrome✓
BTumor-induced osteomalacia
CX-linked hypophosphatemia
DAcute hungry bone syndrome
EAcquired Fanconi syndrome
Why Acute refeeding syndrome is correct
Reintroducing nutrition in a chronically starved patient (anorexia nervosa, BMI 13) triggers an insulin surge that drives phosphate, potassium, and magnesium intracellularly, producing the classic triad of severe hypophosphatemia plus hypokalemia and hypomagnesemia within 72 hours of feeding.
Severe hypophosphatemia (<1.0 mg/dL) depletes ATP and impairs diaphragmatic function, explaining the muscle weakness, paresthesias, confusion, and respiratory compromise.
Prevention is to start nutrition at 25-50% of goal, advance over 5-7 days, and pre-replete phosphate/potassium/magnesium/thiamine, which is the opposite of the full-goal feeding given here.
Why the others are wrong
Acute hungry bone syndrome follows parathyroidectomy (or thyroidectomy for hyperthyroid bone disease), when rapidly remineralizing bone takes up calcium, phosphate, and magnesium; its hallmark is profound, prolonged hypocalcemia. Nothing in this vignette suggests recent neck surgery, and her electrolyte collapse is timed to the start of feeding.
Tumor-induced osteomalacia is caused by an FGF-23-secreting mesenchymal tumor producing chronic bone pain and renal phosphate wasting in adults, not an abrupt electrolyte collapse timed to initiation of feeding.
X-linked hypophosphatemia is an inherited FGF-23 excess disorder presenting in childhood with low phosphate, bowing of the legs, and short stature, not acute weakness triggered by refeeding in an adult.
Acquired Fanconi syndrome — proximal tubular dysfunction does waste both phosphate and potassium, but Fanconi syndrome is a sustained tubulopathy with glycosuria, aminoaciduria, and a non-anion-gap metabolic acidosis, not an abrupt electrolyte collapse 3 days after full-calorie feeding was started in a starved patient.
Question 2RenalMedium
A 47-year-old man with chronic alcohol use disorder is admitted with malnutrition and started on nutritional support. On hospital day 3, routine labs show a serum phosphate of 0.9 mg/dL, with potassium 3.0 mEq/L and magnesium 1.3 mg/dL. He is now weak and tachypneic. His creatinine and eGFR are normal, and he is taking no diuretics. The team wants to confirm whether his hypophosphatemia is from a transcellular shift rather than renal phosphate wasting. Which of the following is the most appropriate next diagnostic test?
APlasma fibroblast growth factor-23
BFractional excretion of phosphate
CSerum 25-hydroxyvitamin D level
DUrine calcium-to-creatinine ratio
ESerum parathyroid hormone level
Reveal answer & full explanation
Correct answer: B — Fractional excretion of phosphate
APlasma fibroblast growth factor-23
BFractional excretion of phosphate✓
CSerum 25-hydroxyvitamin D level
DUrine calcium-to-creatinine ratio
ESerum parathyroid hormone level
Why Fractional excretion of phosphate is correct
FEPO4 (or 24-hour urine phosphate) directly measures renal phosphate handling and is the test that separates renal wasting from non-renal causes.
In a transcellular shift or low intake (refeeding), the kidney conserves phosphate, so FEPO4 is low (<5%) or 24-hour urine phosphate is <100 mg.
A high FEPO4 (>5%) despite low serum phosphate indicates inappropriate renal wasting (PTH excess, FGF-23 excess, Fanconi).
This vignette — severe hypophosphatemia with hypokalemia and hypomagnesemia 72 hours into refeeding a malnourished alcoholic — is classic refeeding syndrome, an insulin-driven shift that a low FEPO4 confirms.
Why the others are wrong
Plasma fibroblast growth factor-23 is useful when a renal phosphate-wasting syndrome is suspected, but it is a later test ordered only after urine studies show renal wasting.
Serum parathyroid hormone level reflects one cause of renal wasting, but PTH alone cannot confirm a shift; localize the loss with urine phosphate first.
Urine calcium-to-creatinine ratio measures urinary calcium excretion, which helps evaluate hypercalciuric disorders such as hereditary hypophosphatemic rickets with hypercalciuria, but it does not assess renal phosphate handling, so it cannot distinguish a transcellular shift from renal phosphate wasting.
Serum 25-hydroxyvitamin D level — vitamin D deficiency is common in malnourished patients with alcohol use disorder and can lower phosphate by reducing intestinal absorption and raising PTH, but a 25-hydroxyvitamin D level does not measure renal phosphate handling, so it cannot distinguish a transcellular shift from renal phosphate wasting.
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Hyperphosphatemia and Hypophosphatemia outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Hyperphosphatemia: CKD/ESKD (most common), tumor lysis syndrome, rhabdomyolysis, hypoparathyroidism, vitamin D toxicity, phosphate-containing bowel preps and laxatives, acidosis, hemolysis (artifactual)
Hypophosphatemia: refeeding syndrome (malnutrition, anorexia, alcoholism, post-bariatric), DKA recovery, respiratory alkalosis (intracellular shift), primary or secondary hyperparathyroidism, X-linked hypophosphatemic rickets, oncogenic osteomalacia (FGF-23–secreting tumor), Fanconi syndrome, IV iron (ferric carboxymaltose, iron isomaltoside), prolonged thiazide or loop diuretic use, vitamin D deficiency
Pathophysiology
Hyperphosphatemia: reduced renal excretion (low GFR) is the dominant mechanism in CKD; high turnover (tumor lysis, rhabdo) or transcellular shift (acidosis) contributes acutely. Chronic hyperphosphatemia drives FGF-23 release, secondary hyperparathyroidism, and CKD-MBD with vascular calcification. Hypophosphatemia: result of decreased intake, decreased absorption, transcellular shift (refeeding insulin surge, respiratory alkalosis), or increased renal loss (PTH, FGF-23 excess, Fanconi). Severe depletion impairs ATP, 2,3-DPG, and cellular function.
Clinical presentation
Symptoms
Hyperphosphatemia: often asymptomatic; pruritus, bone pain, soft-tissue calcification; symptoms of hypocalcemia (precipitation as calcium phosphate) — paresthesias, tetany, seizures
Hyperphosphatemia: signs of associated hypocalcemia (Chvostek, Trousseau), calciphylaxis lesions in ESKD, evidence of vascular calcification
Hypophosphatemia: proximal muscle weakness, decreased respiratory effort, rhabdomyolysis (dark urine, CK elevation), congestive heart failure in severe deficit
Classic findings
Calciphylaxis (ischemic skin necrosis) in dialysis patients with chronically elevated calcium-phosphate product. Refeeding syndrome with severe hypophosphatemia within 72 h of nutrition initiation in a starved patient.
Refeeding syndrome — Severe hypophosphatemia within 72 h of refeeding in a starved or alcoholic patient; also low K, Mg
X-linked hypophosphatemic rickets — FGF-23 excess, low phosphate, normal calcium, short stature, bowing of legs
Oncogenic osteomalacia — Adult with bone pain and severe hypophosphatemia; elevated FGF-23 from mesenchymal tumor
Diagnostic workup
Diagnostic criteria
Cutoffs vary slightly by lab. KDIGO 2017 CKD-MBD suggests lowering elevated phosphate toward the normal range in CKD G3a-G5D, basing treatment on progressively or persistently elevated levels. Hypophosphatemia severity: mild 2.0-2.5, moderate 1.0-2.0, severe <1.0 mg/dL — treatment thresholds depend on severity and symptoms.
Labs
Serum phosphate (fasting; nonhemolyzed) — confirm with repeat sample
Calcium (total and ionized), albumin, magnesium, PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D
BMP, eGFR, BUN/Cr
Urine phosphate (24-hour or fractional excretion of phosphate, FEPO4) to assess renal handling — high in renal wasting, low in intake/shift causes
If unclear etiology: FGF-23 level (elevated in X-linked hypophosphatemia, oncogenic osteomalacia, CKD-MBD), urine glucose/amino acids (Fanconi screen)
CBC, CK, LDH, uric acid (tumor lysis evaluation if relevant)
Imaging
DEXA scan if chronic phosphate disorder
Plain films/MRI for fractures, looser zones (osteomalacia)
68Ga-DOTATATE PET or octreotide scan for suspected FGF-23–secreting tumor
Hypophosphatemia (mild-moderate, asymptomatic): oral repletion — sodium or potassium phosphate (Phos-Nak, K-Phos Neutral); milk and dairy are practical sources
Hypophosphatemia (severe or symptomatic): IV phosphate — sodium phosphate or potassium phosphate; dose by weight and severity (commonly 0.08-0.16 mmol/kg over 6 hours, with larger weight-based doses for severe <1.0 mg/dL; reduce in renal impairment); monitor calcium (avoid precipitation)
Tumor lysis syndrome
Aggressive IV fluids (isotonic saline 2-3 L/m²/day)
Rasburicase for hyperuricemia
Phosphate binders, dialysis if severe
Avoid IV calcium unless symptomatic — risk of calcium phosphate precipitation
Refeeding syndrome
Start nutrition at 25-50% of goal and advance over 5-7 days
Replete phosphate, potassium, magnesium, and thiamine BEFORE and during refeeding
XLH: burosumab (anti-FGF-23 monoclonal antibody) or conventional oral phosphate + calcitriol (older standard with limited efficacy and more adverse effects)
Do not combine burosumab with oral phosphate or active vitamin D — contraindicated because of hyperphosphatemia risk; conventional therapy is an alternative, not an adjunct
Oncogenic (tumor-induced) osteomalacia: localize the tumor (68Ga-DOTATATE PET) and resect it — curative first-line; burosumab or phosphate + calcitriol only if the tumor cannot be localized or curatively resected
Severe CKD-MBD with elevated PTH
Calcimimetic (cinacalcet, etelcalcetide) to lower PTH and indirectly phosphate
Active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol) with caution — can raise phosphate
Parathyroidectomy for refractory tertiary hyperparathyroidism
Second-line / adjunct
Mineral and bone disorder team consultation
Tenapanor — intestinal phosphate absorption inhibitor in dialysis hyperphosphatemia
Complications
Hyperphosphatemia: vascular and soft-tissue calcification, calciphylaxis, secondary/tertiary hyperparathyroidism, renal osteodystrophy, increased cardiovascular mortality in CKD
Severe hypophosphatemia (<1.0 mg/dL) can cause acute respiratory failure from diaphragmatic weakness — always check phosphate in unexplained ventilator dependence.
Watch for refeeding syndrome in anorexia, alcoholism, post-bariatric, and prolonged NPO patients — start nutrition slowly and pre-replete electrolytes.
Calcium-containing binders can worsen vascular calcification — non-calcium binders (sevelamer, lanthanum, ferric citrate) are preferred in dialysis patients with vascular disease.
IV ferric carboxymaltose is an underrecognized cause of hypophosphatemia, sometimes severe and prolonged.
Hyperphosphatemia + hypocalcemia + hyperuricemia + hyperkalemia + AKI = tumor lysis syndrome until proven otherwise.
References
KDIGO CKD-MBD 2017 — KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-Mineral and Bone Disorder (Kidney Int Suppl 2017;7:1-59)
XLH recommendations 2025 — Haffner D et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia (Nat Rev Nephrol 2025;21:330-354)
Refeeding — Friedli N et al. Revisiting the refeeding syndrome: results of a systematic review (Nutrition 2017;35:151-160)
Tumor lysis — Coiffier B et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review (JCO 2008;26:2767-2778)
Practice Renal/Urology questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.